Hiperglikemičnisindrom v bolnišnici. Sladkorna bolezen in operativni poseg. Doc.dr.Vilma Urbančič, dr.med. 1, 2
|
|
- Wilfrid O’Connor’
- 6 years ago
- Views:
Transcription
1 Hiperglikemičnisindrom v bolnišnici. Sladkorna bolezen in operativni poseg. Doc.dr.Vilma Urbančič, dr.med. 1, 2 1 UKC Ljubljana KO EDBP, Diabetološki oddelek 2 UL MF, Katedrazainternomedicino 21. Tečaj hospitalne diabetologije, marec 2016 Namesto uvoda sladkorni bolniki so sprejeti v bolnišnico pogosteje kot ljudje brez sladkorne bolezni vzrok sprejema so običajno spremljajoče bolezni urejanje krvnega sladkorja je le redko v središču pozornosti in je zato pogosto nezadovoljivo Oh diabetes, that s easy, the treatment is insulin, the dose is 25 but I can t remember if it is micrograms or miligrams Neimenovani angleški kardiolog, odgovor na vprašanje, kaj ve o sladkorni bolezni 1
2 Hiperglikemija v bolnišnici 1.Bolniki s predhodno ugotovljeno in zdravljeno sladkorno boleznijo 2.Bolniki s prej neprepoznano sladkorno boleznijo, ki je ugotovljena med hospitalizacijo in mora biti po odpustu iz bolnišnice potrjena s standardnimi diagnostičnimi merili 3.Hospitalna ( stresna ) hiperglikemija: ugotovljena med hospitalizacijo, po odpustu pa se normalizira: Sepsa, travma, opekline, kirurški posegi Hipoksija, hipotermija Okluzivna žilna bolezen (AMI, ICV) Nekaj številk Hiperglikemija je med hospitaliziranimi bolniki pogosta: Cook 2009: 46% v intenzivnih enotah in 32% na navadnih oddelkih Kosiborod 2007: med bolniki z AKS je hiperglikemičnih 78% tistih z znano SB in 26% tistih brez predhodno znane SB Umpierrez 2002: med hospitaliziranimi bolniki 62% normoglikemičnih, 26% z znano SB in 12% z novoodkrito hiperglikemijo. Umpierrez GE. Cleveland Clinic Journal of Medicine, 2011:
3 Glukoza ob sprejemu ter umrljivost v 30 dneh in 1 letu (konc glukoze <6.1; ; ; ; >13.3) Kosiborod M. Circulation 2005: Umpierrez et al,
4 Vzdrževanje normoglikemije Insulin postprandialno obdobje Anabolni in antikatabolni učinki: glikogeneza, lipogeneza, glikoliza in sinteza maščobnih kislin v jetrih, sinteza proteinov Katabolni hormoni stradanje Glukagon, kateholamini, rastni hormon glikogenoliza, glukoneogeneza, lipoliza, ketogeneza Metabolizem ob stresu sekrecija adrenalina, noradrenalina, kortizola in glukagona sekrecija insulina in acetilholina tvorba glukoze v jetrih utilizacija glukoze na periferiji občutljivost perifernih tkiv na insulin občutljivost Langerhansovih otočkov na glukozo Insulinska rezistenca Stresna hiperglikemija 4
5 2015_Nutr Clin Pract_Davidson Akutna stresna hiperglikemija Preneha po odpravi vzroka Ugoden kompenzatorni mehanizem? Neugodni učinki: Oslabljen imunski odziv ( tvorba superoksidnih anionov v nevtrofilcih, slabša fagocitna funkcija 1, vpliv na prirojeno imunost 2 ) Večja pogostnost nozokomialnih okužb 3 Hemodinamske motnje in spremenjene elektromehanske lastnosti miokarda 4 Psihični stres povzroča insulinsko rezistenco in s tem zveča potrebo po insulinu 1 Perner, Intensive Care Med 2003, 2 Turina, Crit Care Med 2005, 3 Khaodhiar, Curr Opin Clin Nutr Metab Care 1999, 4 Marfella, Diabetologia
6 Glikemija pri kritično bolnem Variabilen vnos glukoze Variabilna pot vnosa (enteralno/ parenteralno) Variabilna resorbcija Endogena sekrecija insulina Eksogeni insulin Kinetika insulina Variabilna občutljivost na insulin Variabilno delovanje insulina na nivoju organov Maerz LL and Akhtar S. Curr Opin in Critical Care 2011: Vzroki hiperglikemije pri hospitaliziranih bolnikih Neprepoznana hiperglikemija Stresna hiperglikemija Zdravljenje s kortikosteroidi Manjša stopnja telesne dejavnosti Ukinitev antidiabetične terapije, ki jo je jemal bolnik doma Napake pri zdravljenju, izpuščanje odmerkov Insulinofobija Fonseca V, Reviews in Cardiovascular Medicine,
7 Definicija hiperglikemije koncentracija glukoze v krvi > 7.8mmol/L (140 mg%) Vrednosti, ki so signifikantno oziroma vztrajno višje od te vrednosti, zahtevajo pri hospitaliziranem bolniku ukrepanje. Moghissi et al, American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32: Obravnava bolnika s hiperglikemijo Pri vseh bolnikih s sladkorno boleznijo, ki so sprejeti v bolnišnico, mora biti sladkorna bolezen jasno označena v medicinski dokumentaciji. Pri osebah s hiperglikemijo redno spremljamo glukozo v krvi in zagotovimo dostopnost rezultatov celotnemu zdravstvenemu timu in tudi bolniku Vsem bolnikom s hiperglikemijo sprejemu v bolnišnico določimo HbA1c, če ni bil izmerjen v zadnjih 2 do 3 mesecih Pred načrtovanjem zdravljenja ovrednotimo morebitne srčnožilne in ledvične zaplete. Upoštevamo možnost dodatnega tveganja pri bolnikih, ki imajo nevropatijo, proliferativno retinopatijo, oziroma se zdravijo z metforminom. 7
8 Bolnik s hiperglikemijo Ali se lahko hrani in pije peros? Ali bruha? Diureza? Hemodinamsko stabilen? Stanje zavesti? Terapija pred sprejemom in povod za hiperglikemijo Določitev HbA 1 c List sladkornega bolnika Bolnik, ki ne je in/ali ki je hemodinamsko nestabilen, ne sme dobiti oralnih antidiabetikov (še zlasti ne sekretagogov) in ne insulina subkutano! 8
9 List sladkornega bolnika Dileme Kdaj začeti z insulinom? Vrsta insulina? Začetni odmerek? Terapevtska shema? Kako titrirati? 9
10 Ciljne vrednosti glikemije Umpierrez et al, 2002 Pomen dobre urejenosti glikemije pri kritično bolnem klinične študije: neposredna povezava med stopnjo stresne hiperglikemije ter umrljivostjo kritično bolnih dosledno vzdrževanje normoglikemije pomembno zmanjša obolevnost in umrljivost pri določenih podskupinah kritično bolnih Večina študij v preteklosti: kirurški bolniki Van den Berghe 2006: internistični bolniki Pittas AG. JPEN 2006; 30: van den Berghe G. NEJM 2006; 354:
11 Leuvenska študija <6.1mmol/l <6.1mmol/l >6.1mmol/l >6.1mmol/l Van den Berghe G et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: Randomizirani: 6.104: intenzivno zdravljenje 3.054; konvencionalno
12 8-10 mmol/l mmol/l Konvencionalno: Leuven: > 12 mmol/l NICE-SUGAR: 8-10 mmol/l Leuven umrljivost glede na glukozo na tešče: nad 8.3 > > pod
13 Koncept slabe glikemije Hipoglikemija (< 3.9 mmol/l 70mg%) Hiperglikemija (>7 mmol/l 126 mg%) Glikemična variabilnost (SD > 1.6 mmol/l 29 mg%) Hamer MJ et al. Biology of bone and marrow transpl 2009: Priporočila ACP American College of physicians ADA American Diabetes Association TES The Endocrine Society Papak J, Kansagara D. Am J Cardiol 2012; 110[suppl]:24B 31B 13
14 Ciljne vrednosti glikemije kritično bolni Insulin uvedemo pri persistentni hiperglikemiji 10 mmol/l. Po uvedbi insulina so za večino kritično bolnih priporočljive vrednosti glikemije mmol/l Nižje vrednosti so zaželene (ref.van den Berghe), če jih je mogoče doseči brez večjega tveganja za hipoglikemijo. 1. ADA Standards of Medical Care in Diabetes Diabetes Care 2010; 33 (Suppl 1): S11-S Moghissi E et al. AACE and ADA Consensus Statement on Inpatient Glycemic Control. Diabetes Care 2009; 32(6): NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360: Ciljne vrednosti glikemije bolniki, ki niso kritično bolni Randomiziranih kliničnih raziskav, ki bi opredelile ciljne vrednosti glikemije pri teh bolnikih, ni na voljo. Za večino so ciljne vrednosti KS pred obroki <7.8 mmol/l, oz. naključno <10.0 mmol/l, pod pogojem, da jih lahko dosežemo varno, brez dodatnega tveganja za hipoglikemijo. Strožja merila so primerna za bolnike, ki so bili prej odlično urejeni. Manj stroga merila so dopustna pri bolnikih s hudimi spremljajočimi boleznimi. 14
15 Farmakoterapija SB Oralni antidiabetiki Sulfonilsečnine Meglitinidi Akarboza Metformin Tiazolidindioni Zdravila, ki delujejo na inkretinski sistem Oralna: zaviralci DPP-4 Parenteralna: GLP-1 mimetiki Insulin Terapevtske možnosti Hiperglikemijo v bolnišnici praviloma zdravimo z insulinom. Vsa druga antihiperglikemična zdravila uporabljamo le pri bolnikih, ki niso akutno bolni, se normalno hranijo in imajo urejeno glikemijo. Cardiovascular Diabetology 2009, 8:38 15
16 Čas delovanja Insulin Začetek Vrh Trajanje Kratki analogi min min 4-5 ur Kratki humani min 2-4 ure 5 8 ur NPH 1-3 ure 5-8 ur ur Detemir(Levemir ) 90 min Relativno brez vrha ur Glargin (Lantus ) 90 min Brez vrha 24 ur Degludec(Tresiba ) Steadystatev 3 dneh Brez vrha T 1/2 > 25h Degludec h Zdravljenje z insulinom Kako? Kontinuirana i.v. infuzija: GIK, infuzijska črpalka Subkutano Kateri insulin? Koliko (odmerek)? Kdaj? Pravočasno! ½ h pred jedjo: Actrapid, Humulin R Neposredno pred jedjo ali po jedi: Humalog, NovoRapid, Apidra 16
17 Oprema Stekleničke (viale) Za uporabo s klasičnimi brizgalkami Za dodajanje v infuzijske raztopine Vložki (karpule, penfill) Mehanski injektorji Insulinske črpalke Vnaprej napolnjeni injektorji za enkratno uporabo (prefilled, disposable pens) Nekoč: princip deljenih doz = kratko delujoči humani insulin /6h sc (pred glavnimi obroki in ob 24h) Actrapid Novolet, Humulin R Pen Umaknjena s tržišča v letu 2011 Problem: Kratkodelujočihumani insulin je na voljo le v vialahin karpulah, ne pa v vnaprej napolnjenih injektorjih Viale in klasične brizge: neprecizno odmerjanje pri U-100! Karpule: mehanskih injektorjev ni mogoče sterilizirati 17
18 Degludec Actrapid Novorapid!!! E.K.I. Dileme Kratki analog ni enakovredna zamenjava za kratko delujoči humani insulin. Aplikacija kratkodelujočega humanega insulina iz viale s klasično brizgalko ne omogoča natančnega odmerjanja. Uporaba mehanskih injektorjev, v katerih se menjajo vložki, je v bolnišnici sporna zaradi nezmožnosti sterilizacije injektorja in posledičnega potencialnega prenosa okužb Zato 18
19 Fiziološko urejanje glikemije Nivo insulina Prandialni insulin Koncentracija glukoze: Pred obroki: pod 6.1 Po obrokih: pod 7.5 Bazalni insulin 24-urni profil Bazalni insulin se izloča neprekinjeno 24 ur Vsak bolnik potrebuje bazalni insulin tudi če je tešč zaradi preiskav ali operacije, če se hrani premalo ali sploh nič zaradi nausee ob maligni bolezni ali če ne je zaradi motnje zavesti Prandialna potreba = hrana per os Enako obravnavamo hrano po NGS ali PEG, infuzijo za čas operacije in kompletno parenteralno prehrano! 19
20 Ocena dnevne potrebe 1. celokupna dnevna doza insulina, ki jo je bolnik potreboval pred hospitalizacijo, ob upoštevanju presnovne urejenosti 2. Ocena na podlagi telesne teže: CDO (E) = TT x N (N = ) Donner WT, 2008 Fiziološko nadomeščanje insulina CDO = E/kg TT Bazalni 50% = E/kg TT Insulatard ali Humulin N 0.1E/kg TT pred spanjem ± zjutraj Detemir ali Lantus 0.2E/kg TT pred spanjem Prandialni 50% = 0.2E/kg TT Novorapid, Humalog, Apidra [ ] E/kg TT pred zajtrkom, kosilom, večerjo Korekcijski: 4-6 E kratkega analoga ob KS nad 15 20
21 Kateri insulin? Bazalni: dolgo delujoči analogi humanega insulina (glargin, detemir) ali srednje dolgo deluči humani insulin (NPH). Prandialni in korekcijski odmerki: kratko delujoči humani insulin ali ultrakratkodelujoči analogi (lispro, aspart, glulisin). Razmerje med količino bazalnega in prandialnega insulina je okvirno 50% : 50%. Princip drsečih doz = sliding scale 21
22 Kritično bolni Insulin dovajamo v kontinuirani intravenski infuziji po pisnem ali računalniško podprtem preverjenem protokolu, ki omogoča varno in učinkovito doseganje ciljnih vrednosti glikemije brez dodatnega tveganja za hudo hipoglikemijo NE po principu vse v eni vreči (GIK infuzija) uporabljamo kratkodelujoči, praviloma humani insulin Dileme: Dolgodelujoči insulini pri kritično bolnem? Insulinska črpalka? Bolniki, ki niso kritično bolni Vodenje SB pred, med in po kirurškem posegu Obdobja elektivne teščnosti Akutna poslabšanja urejenosti glikemije Novoodkrita sladkorna bolezen Stresna hiperglikemija Steroidna sladkorna bolezen Vodenje SB pred, med in neposredno po porodu 22
23 Insulin ni namenjen zniževanju glikemije, pač pa vzdrževanju stabilne glikemije Insulin ne deluje za nazaj, ampak vnaprej! Ob normalni vrednosti glukoze v krvi ne smemo ukiniti insulina ali drastično znižati odmerka Razmišljanje po principu vzrok posledica! Tako hipoglikemija kot hiperglikemija sta varnostna zapleta (odklona). 23
24 Kontrole krvnega sladkorja Ob postelji in ne v laboratoriju! Priporočila za pogostnost meritev študij ni, priporočila temeljijo na konsenzualnem mnenju strokovnjakov Bolnik se hrani per os, insulin s.c.: Pred glavnimi obroki redne kontrole Pred spanjem - pogosto Ponoči - občasno 1.5 h po obrokih po potrebi Parenteralna prehrana, insulin v kontinuirani infuziji: Stabilna glikemija: na 3 4 ure Neurejena glikemija: vsako uro!!! Vzroki hipoglikemije pri hospitaliziranih bolnikih Zmanjšan kalorični vnos Izpuščanje obrokov Monitored compliance Medicine/insulin errors Nepredvidljiva resorbcija insulina iz podkožja Spremenjen kognitivni status Fonseca V, Reviews in Cardiovascular Medicine,
25 Prepoznava hipoglikemije Otežena ob motnjah zavesti, pri intubiranih Varno območje glikemije: mmol/l??? Incidenca hipoglikemije v objavljenih študijah: 0% - >30% GIK vs kontinuirana infuzija Ugotavljanje in ustrezno zdravljenje hipoglikemije v vsakdanji praksi je najbrž večji izziv kot v kliničnih študijah. Posledicam hipoglikemije posvečajo v zadnjih letih v kliničnih raziskavah vedno več pozornosti Turina M Crit Care Med2005; 34: S291-S300 Pittas AG. JPEN 2006; 30: Sistemske rešitve za izboljšanje oskrbe SB v bolnišnici Vloga specialista diabetologa Dodatna edukacija zdravstvenega osebja Protokoli za titracijo ne pa sliding scale! Kontinuirana iv infuzija tudi izven intenzivnih enot! Čitljivo pisanje! Both hypoglycemia and hyperglycemia are patient safety issues appropriate for continuous quality improvement (CQI) analysis 25
26 Da! Redno spremljanje vrednosti glikemije Fiziološko nadomeščanje insulina Timski pristop sodelovanje z diabetologom Pravočasno planiranje odpusta Ne! Tablete pri kritično bolnem Sliding scale Insulinofobija Posvet z diabetologom dve uri pred planiranim odpustom 26
27 Viri ADA Standards of Medical Care in Diabetes Diabetes Care 2010; 33(Suppl 1): S11-S61 Wesorick D et al. Management of diabetes and Hyperglycemia in the hospital: a practical guide to subcutaneous insulin use in the non-critically ill, adult patient. Journal of Hospital Medicine 2008; 3 (5, Suppl 5): S17-S28. Moghissi E et al. AACE and ADA Consensus Statement on Inpatient Glycemic Control. Diabetes Care 2009; 32(6): AACE/ACE Glycemic Control Algorithm, Endocr Pract. 2009; 15(6): Moghissi ES. Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes. Mt Sinai J Med Dec 1; 75(6): Donner WT, Klammer KM. Diabetes Management in the Hospital. Med Clin N Am 2008; 92: Operacija 27
28 ... Researchers use statistics the way a drunkard uses a lamp post, more for support than illumination. Winifred Castle Oprijemljivih, z dokazi podprtih priporočil glede optimalnega nivoja glikemije pred, med in po operaciji, ni. In history, thereare no controlgroups. Thereis no one to tellus what might have been. CormacMcCarthy 28
29 Normoglikemija med operacijo (CABG) izboljša perioperativne izide in zmanjša tveganje za rekurentne ishemične dogodke Lazar HL et al. Circulation 2004; Izidi zdravljenja po operacijah na srcu so slabši, če je bila glikemija med operacijo slabo urejena Quattara et al. Anesthesiology 2005; 103: Hiperglikemija pred operacijo (elektivno, ne na srcu ali žilah) je povezana s povečano umrljivostjo zaradi kardiovaskularnih zapletov Noordzij PG et al, European Journal of Endocrinology (2007) Striktno vzdrževanje normoglikemije zniža umrljivost po koronarni revaskularizaciji pod pričakovano glede na Euroscore D Alessandro C et al. J Thorac Cardiovasc Surg 2007;134:29-37 Hiperglikemija pomembno vpliva na prognozo bolnikov z AMI in primarno PTCA, brez prej znane sladkorne bolezni, ni pa neodvisen napovednik umrljivosti pri tistih s prej znano SB Gasior M et al, Cardiology Journal (2008) Intenzivno zdravljenje z insulinom za doseganje normoglikemije med operacijo na srcu ne zmanjša perioperativne obolevnosti in umrljivosti nasprotno, zaradi višje smrtnosti in pogostejših CVI se poraja dvom o utemeljenosti in varnosti takega pristopa Gandhi GY et al, Ann Intern Med 2007; 146: Striktno vzdrževanje normoglikemije pri kritično bolnih bi glede na podatke raziskav utegnilo biti škodljivo, še manj podatkov pa je za bolnike, ki so operirani. Temu dvomu pritrjuje celo van den Berghe Editorial, British Journal of Anaesthesia (2009) Van den Berghe G, Ann Intern Med 2007; 146:
30 SB in operacija Elektivna Urgentna Metformin in perioperativno tveganje Operacija sama po sebi ni dejavnik tveganja za metforminsko laktacidozo, problem so perioperativnizapleti hipotenzija, ishemija miokardna ishemija, sepsa Malo podatkov o metforminu in anesteziji: metfima t ½ < 5.0 h ob normalni funkciji ledvic, večina se ga izloči v manj kot 12 h. Metformin ukinjamo le 24 h pred operacijo, če je potrebna splošna anestezija. Po operaciji ga uvedemo nazaj, ko se začne bolnik spet normalno hraniti per os, če se ni poslabšala ledvična funkcija in če ni pooperativnih zapletov. ChanNN. Br J Anesthes 1999; 83: Lustik. Anesthesiology 1998; 89:
31 Elektivna operacija Peroralna terapija kdaj ukiniti in kdaj uvesti nazaj? Kaj z bazalnim insulinom Kako pokriti infuzijo? Hiperglikemija tik pred načrtovano operacijo Urgentna operacija Kaj jemlje Kdaj je nazadnje vzel? Kaj in kdaj je nazadnje jedel? Kritje infuzij Perfuzor? Kontrole? 31
32 Osnovni principi Med operacijo moramo upoštevati Bazalne potrebe Glukozo v infuzijski raztopini ( prandialna potreba) Osnovno bolezen stres ob okužbi, travmi... Čezmerne poraste glikemije (korekcijski odmerek!) Ocena CDO Kot sicer za urejanje glikemije pri hospitaliziranem bolniku Insulin dovajamo v kontinuirani infuziji Pogoste kontrole! Akutno hiperglikemijo pred kirurškim posegom (tudi če še ni DKA ali DAHS) zdravimo po enakih principih kot akutne zaplete: Infuzija + Kratkodelujoči insulin v iv infuziji, 0.1E/kg TT/h 32
Sladkorna bolezen in kirurški poseg
Sladkorna bolezen in kirurški poseg Doc.dr.Vilma Urbančič, dr.med. UKC Ljubljana KO EDBP, Diabetološki oddelek 1.12.2010 10. Podiplomski tečaj iz hospitalne diabetologije Ljubljana, 24.11. -2.12.2010 Noordzij
More informationProfilaktično zdravljenje hemofilije. Simpozij Bayer Maj 2011
Profilaktično zdravljenje hemofilije Simpozij Bayer Maj 2011 Treatment schedules for adult hemophilia patients Prophylaxis Regular On demand Temporarily Načini zdravljenja krvavitev pri hemofiliji Poznamo
More informationTransition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
More informationFarmakoterapija sladkorne bolezni 3pa 2
Farmakoterapija sladkorne bolezni 3pa 2 Andrej Janež Katedra družinske medicine, Ljubljana 23.10.2014 Izločanje insulina ß-celična funkcija Glukagon Inkretinov Produkcija glukoze v jetrih Jetra GIT Pankreas
More informationAntikoagulantno zdravljenje
Antikoagulantno zdravljenje (novosti s kongresa ASH 2010) Irena Umek Bricman Oddelek za interno medicino SB Slovenj Gradec Podčetrtek, 15.04.2010 Trajanje antikoagulantne terapije Priporočila: 8th ACCP
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationPriporočila za zdravljenje primarne imunske trombocitopenije. Barbara Skopec
Priporočila za zdravljenje primarne imunske trombocitopenije Barbara Skopec ITP = Idiopatična trombocitopenična purpura ITP = primarna imunska trombocitopenija Rodeghiero F, et al. Blood 2009;113:2386
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More information1PODhRANJENOST PRI KLINIČNA PREHRANA IN KRONIČNA VNETNA ČREVESNA BOLEZEN CLINICAL NUTRITION AND INFLAMMATORY BOWEL DISEASE
KLINIČNA PREHRANA IN KRONIČNA VNETNA ČREVESNA BOLEZEN CLINICAL NUTRITION AND INFLAMMATORY BOWEL DISEASE AVTOR / AUTHOR: Asis. Eva Pekaj uni.dipl.ing.živ.tehnol., klinični dietetik Enota za klinično prehrano,
More informationInpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin
Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin David Newman, MD University of North Dakota School of Medicine Sanford Health Big Sky Conference 2017 Dr. David Newman, Personal/Professional
More informationHAP PA-HEN Achieving More Together
HAP PA-HEN Achieving More Together Managing Hyperglycemia in the Hospital: Strategies for Safe and Effective Care Pennsylvania Patient Safety Authority Managing Hyperglycemia in the Hospital: Strategies
More informationGlycemic Control Insulin In The Hospital Setting
Glycemic Control Insulin In The Hospital Setting Glycemic Control The Evidence For Insulin s s Benefit The Mechanism of Insulin s s Benefit The Achievement of Insulin s s Benefit A Few Cases Hyperglycemia
More informationGINKGO BILOBA IN MISELNE SPOSOBNOSTI. Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015
GINKGO BILOBA IN MISELNE SPOSOBNOSTI Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015 KLINIČNO VPRAŠANJE Ali uporaba standardiziranih pripravkov Ginkgo bilobe izboljšuje
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More information11. KORONARNA BOLEZEN Bojan Vrtovec
11. KORONARNA BOLEZEN Bojan Vrtovec Koronarna bolezen je napogostejši vzrok zbolevnosti in umrljivosti bolnikov s sladkorno boleznijo tipa 2. Ker gre za zelo ogroženo populacijo, so priporočila za obravnavo
More information123 Are You Providing Evidence-Based Diabetes Care? - Martin
Donna Martin, DNP, RN, CDE, CMSRN Lewis University Learner will be able to: Identify current inpatient standards of care for patients with diabetes Describe causes of hyperglycemia / hypoglycemia in the
More informationPrincipi PET-CT preiskave. Marko Grmek
Principi PET-CT preiskave Marko Grmek PET-CT PET pozitronska emisijska tomografija CT računalniška tomografija Fuzijska slika Detektor sevanja - PET skener - CT naprava PET-CT preiskava Radiofarmak - 18
More informationSLOVENSKE SMERNICE ZA ZDRAVSTVENO OSKRBO BOLNIKOV S SLADKORNO BOLEZNIJO TIPA 2
Združenje endokrinologov Slovenije, Diabetes forum in Klinični oddelek za endokrinologijo, diabetes in presnovne bolezni Interna klinika Univerzitetni klinični center Ljubljana SLOVENSKE SMERNICE ZA ZDRAVSTVENO
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 1, 218 1:3 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US. About
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More information8. SPREMLJANJE UREJENOSTI GLIKEMIJE V AMBULANTNI OBRAVNAVI
8. SPREMLJANJE UREJENOSTI GLIKEMIJE V AMBULANTNI OBRAVNAVI Špela Volčanšek, Jelka Zaletel Nadzor nad glikemijo je temelj urejanja sladkorne bolezni ter s tem povezanim zmanjševanjem tveganja za kronične
More informationDrug Therapy for Diabetes Mellitus. Adj A/Prof Daniel Chew Dept of Endocrinology 8 th July 2017
Drug Therapy for Diabetes Mellitus Adj A/Prof Daniel Chew Dept of Endocrinology 8 th July 2017 Diabetes Subtypes Optimal Treatment Ominous Octet DeFronzo. DIABETES, VOL. 58, APRIL 2009 Schematic Overview
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, 2018 10:30 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US.
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More information3. DIAGNOZA SLADKORNE BOLEZNI
3. DIAGNOZA SLADKORNE BOLEZNI Maja Ravnik Oblak Mnogo bolnikov s presnovnim sindromom, mejno bazalno glikemijo, moteno toleranco za glukozo in sladkorno boleznijo je neodkritih. Presnovni sindrom, mejna
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationVesna Vasić, dr.med Tanja Mišmaš, dr.med
Vesna Vasić, dr.med Tanja Mišmaš, dr.med 1.. Roger Bouillon,*, Heike Bischoff- Ferrari, Walter Wille: - Vitamin D and Health: PerspecBves From Mice and Man, Journal of Bone and Mineral ResearchVolume
More informationManagement of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Hyperglycemia in Critically ill patients in ICU Settings.
Management of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Guillermo E. Umpierrez, MD, Emory University School of Medicine and Jack Leahy, MD, University of Connecticut Hyperglycemia in Critically
More information9/16/2013. No Conflict of Interest to Disclose
Catie Prinzing MSN, APRN, Clinical Nurse Specialist September 27, 2013 No Conflict of Interest to Disclose List key concepts to determining patient insulin doses during transitions in care Identify 5 points
More informationALI JE DOLGOTRAJNA UPORABA ZAVIRALCEV PROTONSKE ČRPALKE VARNA?
ALI JE DOLGOTRAJNA UPORABA ZAVIRALCEV PROTONSKE ČRPALKE VARNA? Darja Logar, dr. med. Barbara Mazej Poredoš, dr. med. Ljubljana, 18. 10. 2012 Dandanes se izjemno povečuje poraba ZPČ, čemur smo priča tudi
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationDomača naloga 21. modularna skupina
Domača naloga 21. modularna skupina Individualizacija antikoagulantnega zdravljenja glede na genetsko variabilnost v poteh presnove in delovanja varfarina prof. dr. Vita Dolžan, dr. med. Laboratorij za
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationDeepika Reddy MD Department of Endocrinology
Deepika Reddy MD Department of Endocrinology Management of hyperglycemic crisis Review need for inpatient glycemic control Brief overview of relevant trials Case based review of diabetes management strategies/review
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More information19. DIABETIČNA LEDVIČNA BOLEZEN
19. DIABETIČNA LEDVIČNA BOLEZEN Jelka Zaletel, Draženka Pongrac Barlovič, Radovan Hojs Bolniki s sladkorno boleznijo tipa 2 imajo povečano tveganje za kronično ledvično bolezen, pri čemer je najpogostejša
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationANNUAL MEETING 2 #FSHP2017
FSHP Disclosure Strategies for Glycemic Management in the Inpatient Setting: Guidelines vs. Reality Melissa Marshall, PharmD, BCPS Jeffrey Ruff, PharmD We do not have (nor does any immediate family member
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationImplementing Hospital Policies & Protocols
Implementing Hospital Policies & Protocols Jane Jeffrie Seley DNP MPH GNP BC-ADM CDE CDTC FAADE FAAN Division of Endocrinology, Diabetes & Metabolism NewYork-Presbyterian Hospital Weill Cornell Medicine
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationInsulin Therapy Management. Insulin Therapy
Insulin Therapy Management Insulin Therapy Contents Insulin and its effect on glycemic control Physiology of insulin secretion Insulin pharmacokinetics and regimens Insulin dose adjustment for pregnancy
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationControl of Blood Glucose in the ICU: Reconciling the Conflicting Data
Control of Blood Glucose in the ICU: Reconciling the Conflicting Data Steven E. Nissen MD Disclosure Consulting: Many pharmaceutical companies Clinical Trials: AbbVie, Amgen, Astra Zeneca, Esperion, Eli
More informationGlucose Management in the ICU: The Role of the Pharmacist
Objectives Glucose Management in the ICU: The Role of the Pharmacist James Gilmore PharmD, BCPS Senior Pharmacist- Surgical Intensive Care Unit Brigham and Women s Hospital Boston, MA Evaluate primary
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationOsnove antikoagulacijskega zdravljenja. Maja Jošt, Erika Oblak
Osnove antikoagulacijskega zdravljenja Maja Jošt, Erika Oblak Golnik, september 2011 Naša slikca SMERNICE: KDO? KDAJ? ZAKAJ? KOLIKO ČASA? KATERO ZDRAVILO? Mavri A, Vene N. Smernice za vodenje antikoagulacijskega
More informationHIV/AIDS UPDATE Janez Tomažič Klinika za infekcijske bolezni in vročinska stanja Katedra za infekcijske bolezni in epidemiologijo
HIV/AIDS UPDATE 2017 Janez Tomažič Klinika za infekcijske bolezni in vročinska stanja Katedra za infekcijske bolezni in epidemiologijo Patogeneza okužbe s HIV 1. Sesutje imunskega sistema KLINIČNE OPREDELITVE
More informationAnaliza preživetja. Izbrana poglavja iz biomedicinske informatike 2011/2012, LBM2. Asist. dr. Igor Locatelli, mag. farm.
Analiza preživetja Izbrana poglavja iz biomedicinske informatike 2011/2012, LBM2 Asist. dr. Igor Locatelli, mag. farm. Ljubljana, 16. 12. 2011 Analiza preživetja Survival analysis Proučevanje (modeliranje)
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More informationType I Type II Insulin Resistance
Insulin An aqueous hormonal solution made in the pancreas. Affects metabolism by allowing glucose to leave the blood and enter the body cells, preventing hyperglycemia. It is measured in units, e.g. 100
More informationInpatient Glycemic Management 2016
2016 Jim Chamberlain MD Medical Director for Diabetes Services St. Mark s Hospital and St. Mark s Diabetes Center Salt Lake City, Utah Disclosures Speakers Bureaus Merck & Co. Janssen Pharmaceutical Companies
More informationIn - Hospital Diabetes Care. A review and personal experience
In - Hospital Diabetes Care A review and personal experience Hyperglycemia in the Hospital The Problem Hospitalizations with Diabetes http://www.cdc.gov/diabetes/statistics/dmany/fig1.htm Prevalence of
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationConverting lantus to humalog 75 25
P ford residence southampton, ny Converting lantus to humalog 75 25 This page includes the following topics and synonyms: Insulin Dosing in Type 2 Diabetes, Insulin Dosing in Type II Diabetes. Thiazide
More informationOptimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action
Optimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action Learning Objectives Identify patient situations where specific attention to glycemic control is warranted Determine
More informationMeeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes
More information15. DIABETIČNA LEDVIČNA BOLEZEN Jelka Zaletel Vrtovec, Draženka Pongrac Barlovič
15. DIABETIČNA LEDVIČNA BOLEZEN Jelka Zaletel Vrtovec, Draženka Pongrac Barlovič Bolniki s sladkorno boleznijo tipa 2 sodijo med ljudi s povečanim tveganjem za kronično ledvično bolezen, najpogostejša
More informationImplementing Glucose Control in 2009 and Beyond: Changes in Patterns and Perceptions
Implementing Glucose Control in 2009 and Beyond: Changes in Patterns and Perceptions Charles C. Reed MSN, RN, CNRN Patient Care Coordinator Surgical Trauma ICU University Hospital San Antonio, Texas Relationships
More informationRecent Advances in the Management of Diabetes
Recent Advances in the Management of Diabetes Raja Hanania, R.Ph,CDM,CDE,LDE,BCPS Clinical Pharmacy Specialist IU Health Bloomington Hospital Bloomington, Indiana Indiana Pharmacists Alliance Annual Convention
More informationMedications for Diabetes
Medications for Diabetes Sweet, but not too sweet Colette Raymond, Pharm D June 15, 2011 Learning Objectives At the end of this presentation you should be able to: Understand the prevalence and types of
More informationMartin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine
The Approach to Inpatient Hyperglycemia Martin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine Great Lakes Hospital Medical Symposium May 7th 2010 Further Increases in the Prevalence of Diabetes
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationDrug Use Criteria: Exogenous Insulin Products
Texas Vendor Program Use Criteria: Exogenous Products Publication History 1. Developed June 2017. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be
More informationLet s not sugar coat it: Promoting excellence in glucose control in hospitalized and perioperative patients WELCOME!
Let s not sugar coat it: Promoting excellence in glucose control in hospitalized and perioperative patients WELCOME! 1. Evaluate the evidence for variable glycemic control for patients in the hospital
More informationHow to manage type 2 diabetes in medical and surgical patients in the hospital
MEDICAL GRAND ROUNDS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will learn the relationship between glycemic control and clinical outcomes in hospitalized medical and surgical patients who are not in an
More informationCase Study: Competitive exercise
Case Study: Competitive exercise 32 year-old cyclist Type 1 diabetes since age 15 Last HbA1 54 No complications and hypo aware On Humalog 8/8/8 and Levemir 15 Complains about significant hypoglycaemia
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationKAKOVOST IN VARNOST/QUALITY AND SAFETY
KAKOVOST IN VARNOST/QUALITY AND SAFETY Smernice za obravnavo bolnikov z anevrizmo trebušne aorte Guidelines for the management of patients with abdominal aortic aneurysm Matija Kozak, 1 Beno Polanec, 2
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationZdrav življenjski slog Zdrav krvni tlak. Svetovna liga za hipertenzijo
Zdravživljenjskislog Zdravkrvnitlak Svetovnaligazahipertenzijo Svetovnidan hipertenzije17.maj2012 Kajjehipertenzija? Hipertenzijajekroninostanje,kjerjekrvni tlakzvišan.mnogiljudjeimajozvišantlak mnogaleta,nedabisetegazavedali.
More informationPerioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction
Perioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction Luigi Meneghini, MD, MBA Professor, Internal Medicine (Endocrinology), UT Southwestern Medical
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationInsulin Order Sets & In-Hospital Management of Diabetes
Insulin Order Sets & In-Hospital Management of Diabetes 416591 Table of Contents Key elements from Diabetes Canada 2018 Clinical Practice Guidelines Introduction........................................................
More informationALI SO PRIPRAVKI GLUKOZAMINA UČINKOVITI V TERAPIJI GONARTROZE?
ALI SO PRIPRAVKI GLUKOZAMINA UČINKOVITI V TERAPIJI GONARTROZE? SPECIALIZACIJA IZ DRUŽINSKE MEDICINE MODUL: NA DOKAZIH TEMELJEČA MEDICINA 16. SKUPINA AVTORJI: MIRJANA NINKOV MILA MRŠIĆ OLIVER ILIĆ OPIS
More informationGetting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes
Getting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes Kristi Kulasa, MD Associate Clinical Professor of Medicine Director, Inpatient Glycemic Control University of California
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More informationPROGRAM STROKOVNEGA SREČANJA... 1
Kazalo Stran PROGRAM STROKOVNEGA SREČANJA... 1 SLADKORNI BOLNIK TIPA 2 IN PATRONAŽNA MEDICINSKA SESTRA Mitja Krajnc, dr. med., prim. asist. Miro Čokolič, dr. med.... 3 PATRONAŽNA MEDICINSKA SESTRA IN SLADKORNI
More informationSašo Duh, Mojca Prica, Manja Vivod NA DOKAZIH TEMELJEČA MEDICINA MODULARNA NALOGA
Sašo Duh, Mojca Prica, Manja Vivod NA DOKAZIH TEMELJEČA MEDICINA MODULARNA NALOGA OPIS PROBLEMA OZ. VPRAŠANJA VKLJUČNO Z OPISOM POPULACIJE, NA KATERO SE PROBLEM NANAŠA Povezava med pomanjkanjem vitamina
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationCurrent Controversies in Diabetes Control
Current Controversies in Diabetes Control Dara P. Schuster, MD, FACE ADA, AACE/ACE, and ACP Guidelines: Treatment Goals for A1C, FPG, and PPG Parameter Normal 1,2 Level ADA 3 Goal AACE/ACE 2 Goal ACP 4
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More information